Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)

C4 Therapeutics has reported Non Operating Investment Income over the past 6 years, most recently at -$73000.0 for Q2 2025.

  • For Q2 2025, Non Operating Investment Income fell 21.67% year-over-year to -$73000.0; the TTM value through Jun 2025 reached $410000.0, down 69.27%, while the annual FY2025 figure was -$3000.0, 101.67% down from the prior year.
  • Non Operating Investment Income for Q2 2025 was -$73000.0 at C4 Therapeutics, down from -$10000.0 in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $1.7 million in Q1 2023 and troughed at -$2.9 million in Q1 2022.
  • A 5-year average of -$2388.9 and a median of -$66500.0 in 2024 define the central range for Non Operating Investment Income.
  • On a YoY basis, Non Operating Investment Income climbed as much as 1350.0% in 2021 and fell as far as 12500.0% in 2021.
  • Year by year, Non Operating Investment Income stood at -$620000.0 in 2021, then skyrocketed by 305.16% to $1.3 million in 2022, then plummeted by 38.92% to $777000.0 in 2023, then tumbled by 151.74% to -$402000.0 in 2024, then surged by 81.84% to -$73000.0 in 2025.
  • Business Quant data shows Non Operating Investment Income for CCCC at -$73000.0 in Q2 2025, -$10000.0 in Q1 2025, and -$402000.0 in Q4 2024.